- Home
- AVIR vs CRVS Comparison
AVIR vs CRVS Comparison
Compare AVIR & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVIR
- CRVS
- Stock Information
- Founded
- AVIR 2012
- CRVS 2014
- Country
- AVIR United States
- CRVS United States
- Employees
- AVIR N/A
- CRVS N/A
- Industry
- AVIR Medicinal Chemicals and Botanical Products
- CRVS Biotechnology: Pharmaceutical Preparations
- Sector
- AVIR Health Care
- CRVS Health Care
- Exchange
- AVIR Nasdaq
- CRVS Nasdaq
- Market Cap
- AVIR 273.0M
- CRVS 305.4M
- IPO Year
- AVIR 2020
- CRVS 2016
- Fundamental
- Price
- AVIR $3.67
- CRVS $3.91
- Analyst Decision
- AVIR Hold
- CRVS Strong Buy
- Analyst Count
- AVIR 1
- CRVS 4
- Target Price
- AVIR $6.00
- CRVS $15.00
- AVG Volume (30 Days)
- AVIR 410.2K
- CRVS 1.2M
- Earning Date
- AVIR 08-06-2025
- CRVS 08-05-2025
- Dividend Yield
- AVIR N/A
- CRVS N/A
- EPS Growth
- AVIR N/A
- CRVS N/A
- EPS
- AVIR N/A
- CRVS N/A
- Revenue
- AVIR N/A
- CRVS N/A
- Revenue This Year
- AVIR N/A
- CRVS N/A
- Revenue Next Year
- AVIR N/A
- CRVS N/A
- P/E Ratio
- AVIR N/A
- CRVS N/A
- Revenue Growth
- AVIR N/A
- CRVS N/A
- 52 Week Low
- AVIR $2.46
- CRVS $1.75
- 52 Week High
- AVIR $4.15
- CRVS $10.00
- Technical
- Relative Strength Index (RSI)
- AVIR 76.11
- CRVS 55.29
- Support Level
- AVIR $3.15
- CRVS $3.55
- Resistance Level
- AVIR $3.35
- CRVS $4.38
- Average True Range (ATR)
- AVIR 0.13
- CRVS 0.31
- MACD
- AVIR 0.03
- CRVS -0.01
- Stochastic Oscillator
- AVIR 83.81
- CRVS 61.68
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).
About CRVS Corvus Pharmaceuticals Inc.
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).